​

Forte Biosciences Stock (NASDAQ:FBRX)

ForecastOwnershipFinancialsChart
Forte Biosciences by TradingView

Previous Close

$76.50

52W Range

$9.10 - $76.68

50D Avg

$28.50

200D Avg

$25.49

Market Cap

$1.57B

Avg Vol (3M)

$817.57K

Beta

2.84

Div Yield

-

FBRX Company Profile

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

22

IPO Date

Apr 13, 2017

Website

FBRX Performance

FBRX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-70.66M$-36.60M$-32.49M
Net Income$-69.38M$-35.48M$-31.48M
EBITDA$-70.66M$-35.44M$-32.48M
Basic EPS$-4.71$-12.17$-24.92
Diluted EPS$-4.71$-12.17$-24.92

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 21May 10, 21 | 4:30 PM

Peer Comparison

TickerCompany
ACTUActuate Therapeutics Inc
CRBPCorbus Pharmaceuticals Holdings, Inc.
MOLNMolecular Partners AG
ALECAlector, Inc.
CRDFCardiff Oncology, Inc.
NKTXNkarta, Inc.
FATEFate Therapeutics, Inc.
ELTXElicio Therapeutics, Inc.
PEPGPepGen Inc.